# Regeneron Pharmaceuticals, Inc. (REGN) — Q4-2025 Earnings Results

**Report date:** 2026-01-30 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q4-2025

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 1.07%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $11.44 | N/A | +38.18% |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in their product pipeline and the company's ability to navigate market challenges. However, they acknowledged the competitive landscape.

**Key quotes:**

> Management highlighted strong performance in key products.

> They emphasized ongoing investment in R&D to drive future growth.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron Pharmaceuticals reported strong earnings per share, exceeding expectations significantly. However, the stock fell by 1.07% in reaction to the lack of revenue data and guidance. Investors may be cautious due to the absence of future projections, despite the positive EPS surprise.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q4-2025_